patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days background of cardiac transplant surgery implanted defibrillator (icd) in the last three months implanted left-ventricular assist device (lvad) acute coronary syndrome (acs) within 30 days percutaneous coronary intervention (pci) within 30 days receiving any immuno-suppressive agent other than dexamethasone history of qtc interval prolongation qtc interval > 500 msec treated with strong inducers of cyp3a4 or cyp2c19 chronic renal failure, determined as egfr < 30 ml/min elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection current participation in any research study involving investigational drugs or devices with the exception of dexamethasone, remdesivir, baricitinib plus remdesivir, convalescent plasma or monoclonal antibodies against the sars-cov-2 virus or any other therapy approved under emergency use in the region for treatment of covid-19 inability or unwillingness to give informed consent ongoing drug, alcohol or cannabis abuse women who are pregnant or breastfeeding any factor, which would make it unlikely that the patient can comply with the study procedures hemoglobin <8.5 gm/dl leukocyte count < 3000/ mm3 platelets < 100,000 / mm3 current diagnosis of cancer, with the exception of non-melanoma skin cancer showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening any cannabinoid intake in the past month body weight > 170 kg

patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days background of cardiac transplant surgery implanted defibrillator (icd) in the last three months implanted left-ventricular assist device (lvad) acute coronary syndrome (acs) within 30 days percutaneous coronary intervention (pci) within 30 days receiving any immuno-suppressive agent other than dexamethasone history of qtc interval prolongation qtc interval > 500 msec treated with strong inducers of cyp3a4 or cyp2c19 chronic renal failure, determined as egfr < 30 ml/min elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection current participation in any research study involving investigational drugs or devices with the exception of dexamethasone, remdesivir, baricitinib plus remdesivir, convalescent plasma or monoclonal antibodies against the sars-cov-2 virus or any other therapy approved under emergency use in the region for treatment of covid-19 inability or unwillingness to give informed consent ongoing drug, alcohol or cannabis abuse women who are pregnant or breastfeeding any factor, which would make it unlikely that the patient can comply with the study procedures hemoglobin <8.5 gm/dl leukocyte count < 3000/ mm3 platelets < 100,000 / mm3 current diagnosis of cancer, with the exception of non-melanoma skin cancer showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening any cannabinoid intake in the past month body weight > 170 kg

patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days background of cardiac transplant surgery implanted defibrillator (icd) in the last three months implanted left-ventricular assist device (lvad) acute coronary syndrome (acs) within 30 days percutaneous coronary intervention (pci) within 30 days receiving any immuno-suppressive agent other than dexamethasone history of qtc interval prolongation qtc interval > 500 msec treated with strong inducers of cyp3a4 or cyp2c19, as listed in appendix 17.8 chronic renal failure, determined as egfr < 60 ml/min elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection current participation in any research study involving investigational drugs or devices with the exception of dexamethasone inability or unwillingness to give informed consent ongoing drug, alcohol or cannabis abuse women who are pregnant or breastfeeding any factor, which would make it unlikely that the patient can comply with the study procedures hemoglobin <8.5 gm/dl leukocyte count < 3000/ mm3 platelets < 100,000 / mm3 current diagnosis of cancer, with the exception of non-melanoma skin cancer showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening

patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days background of cardiac transplant surgery implanted defibrillator (icd) in the last three months implanted left-ventricular assist device (lvad) acute coronary syndrome (acs) within 30 days percutaneous coronary intervention (pci) within 30 days receiving any immuno-suppressive agent other than dexamethasone history of qtc interval prolongation qtc interval > 500 msec treated with strong inducers of cyp3a4 or cyp2c19, as listed in appendix 17.8 chronic renal failure, determined as egfr < 60 ml/min elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection current participation in any research study involving investigational drugs or devices with the exception of dexamethasone inability or unwillingness to give informed consent ongoing drug, alcohol or cannabis abuse women who are pregnant or breastfeeding any factor, which would make it unlikely that the patient can comply with the study procedures hemoglobin <8.5 gm/dl leukocyte count < 3000/ mm3 platelets < 100,000 / mm3 current diagnosis of cancer, with the exception of non-melanoma skin cancer showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening

1. patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days 2. background of cardiac transplant surgery 3. implanted defibrillator (icd) in the last three months 4. implanted left-ventricular assist device (lvad) 5. acute coronary syndrome (acs) within 30 days 6. percutaneous coronary intervention (pci) within 30 days 7. receiving any immuno-suppressive agent other than dexamethasone 8. history of qtc interval prolongation 9. qtc interval > 500 msec 10. treated with strong inducers of cyp3a4 or cyp2c19, as listed in appendix 17.8 11. chronic renal failure, determined as egfr < 60 ml/min 12. elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln 13. bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection 14. current participation in any research study involving investigational drugs or devices with the exception of dexamethasone 15. inability or unwillingness to give informed consent 16. ongoing drug, alcohol or cannabis abuse 17. women who are pregnant or breastfeeding 18. any factor, which would make it unlikely that the patient can comply with the study procedures 19. hemoglobin <8.5 gm/dl 20. leukocyte count < 3000/ mm3 21. platelets < 100,000 / mm3 22. current diagnosis of cancer, with the exception of non-melanoma skin cancer 23. showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening

1. patients who have received vasopressors, extracorporeal membrane oxygenation and mechanical ventilation within last 30 days 2. background of cardiac transplant surgery 3. implanted defibrillator (icd) in the last three months 4. implanted left-ventricular assist device (lvad) 5. acute coronary syndrome (acs) within 30 days 6. percutaneous coronary intervention (pci) within 30 days 7. receiving any immuno-suppressive agent other than dexamethasone 8. history of qtc interval prolongation 9. qtc interval > 500 msec 10. treated with strong inducers of cyp3a4 or cyp2c19, as listed in appendix 17.8 11. chronic renal failure, determined as egfr < 60 ml/min 12. elevated alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal (uln) or alt or ast >3x uln plus bilirubin >2x uln 13. bacterial sepsis, defined as documented bacteremia at the time of presentation or other active bacterial infection 14. current participation in any research study involving investigational drugs or devices with the exception of dexamethasone 15. inability or unwillingness to give informed consent 16. ongoing drug, alcohol or cannabis abuse 17. women who are pregnant or breastfeeding 18. any factor, which would make it unlikely that the patient can comply with the study procedures 19. hemoglobin <8.5 gm/dl 20. leukocyte count < 3000/ mm3 21. platelets < 100,000 / mm3 22. current diagnosis of cancer, with the exception of non-melanoma skin cancer 23. showing suicidal tendency as per the columbia-suicide severity rating scale (c-ssrs) administered at screening